Command Palette

Search for a command to run...

Preprint WatchModerateNovember 7th, 2026

Isocaloric restriction of a high-fat diet under TAK-242 administration: metabolic and gut microbial responses in mice

Jeong, E.; Chae, S.; Eun, S.; Chai, H.; Lee, S.

Pharmacological inhibition of TLR4 signalling with TAK-242, combined with isocaloric restriction of a high-fat diet, is proposed to normalize visceral adiposity, intestinal barrier gene expression and the faecal microbial community in mice.

Moderate contradiction

2 prior failures

Two documented clinical failures match this mechanism, or a single Phase 3 failure is on record.

This preprint uses TAK-242, the same TLR4 signalling inhibitor that already carries a terminated clinical program in the Claidex graph, and extends its rationale into diet-induced obesity and gut barrier biology. Two TLR4 programs have stopped, tak-242-resatorvid-tlr4-acute-on-chronic-liver-failure-phase2-enrollment-collapse and paridiprubart-eb05-tlr4-covid19-ards-phase2-3-sponsor-termination. Neither stopped on a clean efficacy readout, so TLR4 blockade remains clinically untested rather than disproven, and that is the risk. A mouse study that reports normalization across several loosely coupled endpoints, in a design with no vehicle-injected arm, is weak ground for a new indication on a target whose two clinical attempts never produced an interpretable efficacy result.

Abstract excerpt

High-fat feeding promotes obesity in mice largely by increasing energy intake, so diet composition and energy intake are hard to separate without pair-feeding. We previously showed that isocaloric restriction normalizes body weight, glycemia and plasma lipids but not visceral adiposity, adipose inflammation or the fecal microbial community. We hypothesized that, during administration of the TLR4 signaling inhibitor TAK-242, matching energy intake to that of low-fat controls would normalize adiposity, intestinal barrier gene expression and the fecal microbial community. Male C57BL/6 mice (n = 8 per group) received a low-fat diet, a high-fat diet ad libitum, or a high-fat diet pair-fed to controls from week 0 or week 5 for 12 weeks; TAK-242 (3 ug/g, three times weekly) was given to every group from week 0.4, with no vehicle-injected arm. Intake did not differ among groups during a three-week low-fat acclimation (P = .88); over the 12 weeks on the assigned diets the ad libitum high-fat group ate 5.5% more than controls (P = .50). Over the full trajectory the ad libitum high-fat group gained 0.48 g/week more than controls (group x week, P = .012); both pair-fed groups had lower fasting glucose than that group. Adipocyte diameter, visceral fat proportion, ileal barrier genes, CCK-induced satiation and microbial alpha diversity did not differ significantly among groups. Adipose Ccl2 expression differed (P = .043, exploratory), as did fecal community composition (PERMANOVA P = .022), although no pairwise contrast survived correction. Energy restriction did not return the microbial community toward the low-fat profile.

Matching Claidex post-mortems

2 of 2 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.